Skip to main content
SpringerLink
Log in

Phase II trial of carboplatin in patients with advanced melanoma

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We report the results of a phase II evaluation of carboplatin (CBDCA) in 45 patients with advanced malignant melanoma. Of the 43 evaluable patients, 6 had been treated previously with chemotherapy; 11 had been treated with immunotherapy. The initial dose was 400 mg/m2 i.v. every 4 weeks; the dose was modified as required to achieve moderate myelosuppression. There was one complete response (duration 16 months) and six partial responses, for a major objective response rate of 16%. Toxicity consisted primarily of acute nausea and vomiting, and thrombocytopenia. The activity of CBDCA in this disease is similar to that of cisplatin and dacarbazine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60: 165–176, 1976

    Google Scholar 

  2. Constanza ME, Nathanson L, Schoenfeld D, Wolter J, Colsky J, Regelson W, Cunningham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40: 1010–1015, 1977

    Google Scholar 

  3. Luikart SD, Kennealey GT, Kirkwood JM: Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164–168, 1984

    CAS  PubMed  Google Scholar 

  4. Wittes RE, Wittes JT, Golbey RB: Combination chemotherapy in metastatic malignant melanoma. Cancer 41: 415–421, 1978

    CAS  PubMed  Google Scholar 

  5. Vorobiof DA, Sarli R, Falkson G: Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 70: 927–928, 1986

    Google Scholar 

  6. Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66: 31–35, 1982

    Google Scholar 

  7. Karakousis CP, Getaz EP, Bjornsson S, Henderson ES, Irequi M, Martinez L, Ospina J, Cavins J, Preisler H, Holyoke E, Holtermann O: cis-Dichlorodiammineplatinum (II) and DTIC in malignant melanoma. Cancer Treat Rep 63: 2009–2010, 1979

    Google Scholar 

  8. National Cancer Institute of Canada Melanoma Group: Vinblastine, bleomycin, and cis-platinum for the treatment metastatic malignant melanoma. J Clin Oncol 2: 131–134, 1984

    Google Scholar 

  9. Carey RW, Anderson JR, Green M, Ellison RR, Nathanson L, Kennedy B J: Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B. Cancer Treat Rep 70: 329–331, 1986

    Google Scholar 

  10. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarble P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405, 1984

    Google Scholar 

  11. McClay EF, Mastrangelo MJ, Bellet RE, Berd D: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465–469, 1987

    Google Scholar 

  12. Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM: Treatment of metastatic malignant melanoma with dacarbazine and cisplatin. Cancer Treat Rep 71: 877–878, 1987

    Google Scholar 

  13. Leyvraz S, Ohnuma T, Lassus M, Holland JF: Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 3: 1385–1392, 1985

    Google Scholar 

  14. Evans LM, Casper ES, Rosenbluth R, Participating Community Clinical Oncology Program investigators: Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71: 171–172, 1987

    Google Scholar 

  15. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN: Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6: 1636–1648, 1988

    Google Scholar 

  16. Vershraegen CF, Kleeberg UR, Truchetet F, Israels P, Aapro M, Mulder J, Thomas D, Rosencweig M: Phase II trial of carboplatin versus iproplatin in disseminated malignant melanoma. Proc ASCO 7: 246, 1988

    Google Scholar 

  17. Glover D, Glick JH, Weiler C, Fox K, Guerry D: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574–578, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Solid Tumor Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College New York, NY, USA

    Ephraim S. Casper & Dean Bajorin

Authors
  1. Ephraim S. Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casper, E.S., Bajorin, D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 8, 187–190 (1990). https://doi.org/10.1007/BF00177256

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177256

Key words

Search

Navigation